Moderna and Merck's Personalized Melanoma Vaccine Shows Promising Results

Moderna and Merck have announced promising late-stage results for their personalized mRNA melanoma vaccine, intismeran autogene. When combined with Keytruda immunotherapy, this treatment reduced the risk of melanoma recurrence.

This breakthrough could bring mRNA vaccines closer to broader use in cancer treatment. Unlike preventive vaccines, therapeutic cancer vaccines help the immune system recognize and destroy tumor cells.

Messenger RNA technology has been studied for decades and became widely known during the COVID-19 pandemic. It delivers a brief set of instructions to cells for producing a specific protein, which the immune system then learns to recognize as a target.